The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT02300233

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02300233
  • EudraCT 2014-003434-93
Other papers using this trial's data
  • Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial The lancet. Diabetes & endocrinology, 2021-05 DOI, PubMed 33798466

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, France, Germany, Netherlands, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02300233. Randomized; quadruple masking; primary purpose treatment. Start 2015-02-05 (actual); primary completion 2016-07-27 (actual). Results posted on 2022-04-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
Condition
Hypertriglyceridemia
Intervention (Drug)
Volanesorsen
Intervention (Drug)
Placebo
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)
Collaborator
Akcea Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02300233
Content hash
d128cb0718bb79a836dab9f24dd63a1107e3ec8c79c0e193d080a6579b00ac92